Three of these drugs—donepezil, galantamine and rivastigmine—are acetylcholinesterase (AChE) inhibitors, developed on the cholinergic hypothesis which proposed AD was due to preferential loss of cholinergic neurons (Bartus 2000). The gene discussed is ACHE; the disease is Alzheimer disease.